Affiliation: Pfizer Global Research and Development
- Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Alessandra Blasina
Department of Cancer Biology, Pfizer Global Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA
Mol Cancer Ther 7:2394-404. 2008..In xenografts, PF-00477736 enhanced the antitumor activity of gemcitabine in a dose-dependent manner. PF-00477736 combinations were well tolerated with no exacerbation of side effects commonly associated with cytotoxic agents...
- PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activityJing Yuan
Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
Mol Cancer Ther 10:2189-99. 2011..In summary, PF-04691502 is a potent dual PI3K/mTOR inhibitor with broad antitumor activity. PF-04691502 has entered phase I clinical trials...
- Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitorsMin Teng
Department of Medicinal Chemistry, Pfizer Global Research and Development, La Jolla, Inc, 10770 Science Center Drive, San Diego, California 92121 1194, USA
J Med Chem 50:5253-6. 2007..Compound 10c, showing no single agent effect, potentiated the antiproliferative effect of Gemcitabine in both prostate and breast cancer cell lines...
- Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell lineDouglas D Fang
Oncology Research Unit, Pfizer, Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA
Front Med 7:462-76. 2013....